XML 22 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Operating activities:    
Net loss $ (68,498) $ (40,300)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation and amortization 2,218 513
Equity-based compensation 11,894 6,816
Non-cash interest   8,050
Loss from disposal of property and equipment   28
Unrealized foreign currency remeasurement loss (9) (7)
Gain on extinguishment of convertible loan   (11,482)
Loss from equity method investment 1,310 686
Changes in:    
Restricted cash (4) (2,453)
Accounts receivable (54) (1,753)
Prepaid expenses and other assets (304) (694)
Accounts payable and accrued expenses (2,979) 3,275
Deferred revenue 2,043 1,220
Deferred rent (903) 196
Other liabilities, net 31 11
Net cash used in operating activities (55,255) (35,894)
Investing activities:    
Purchase of property and equipment (7,609) (2,788)
Proceeds from contribution of intellectual property to equity method investee   20,000
Purchase of available for sale debt security (500) (100)
Net cash (used in) provided by investing activities (8,109) 17,112
Financing activities:    
Proceeds from issuance of common shares   16
Issuance costs for preferred share financings   (1,810)
Payment of public offering costs   (2,677)
Proceeds from issuance of convertible loans   35,000
Proceeds from exercise of options 1,324  
Net cash provided by financing activities 1,324 91,454
Effect of exchange rate changes on cash 39 (20)
(Decrease) increase in cash (62,001) 72,652
Cash, beginning of period 315,520 155,961
Cash, end of period 253,519 228,613
Supplemental disclosure of non-cash investing and financing activities    
Property and equipment purchases in accounts payable and accrued expenses $ 118 246
Conversion of Vertex convertible loan and accrued interest   61,929
Noncash contribution of intellectual property to Casebia Therapeutics LLP   36,372
Issuance costs for public offering in accounts payable and accrued expenses   825
Series A-3 Redeemable Convertible Preferred Shares [Member]    
Financing activities:    
Proceeds from issuance of preferred shares   22,850
Series B Redeemable Convertible Preferred Shares [Member]    
Financing activities:    
Proceeds from issuance of preferred shares   $ 38,075